MASI Stock Recent News

Masimo Corporation (NASDAQ:MASI ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Katie Szyman - Chief Executive Officer Micah Young - Executive Vice President, Chief Financial Officer Eli Kammerman - Vice President of Business Development, Investor Relations Conference Call Participants Frederick Wise - Stifel Financial Vik Chopra - Wells Fargo Jason Bednar - Piper Sandler Mike Matson - Needham Matt Taylor - Jeffries Michael Polark - Wolfe Operator Good afternoon, ladies and gentlemen. And welcome to Masimo's First Quarter 2025 Earnings Conference Call.

Masimo (MASI) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $0.77 per share a year ago.

Samsung Electronics said on Wednesday its unit Harman International signed a deal to acquire U.S. firm Masimo's audio business for $350 million.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced that it has entered into a definitive agreement to sell its Sound United consumer audio business to HARMAN International (“HARMAN”), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., for an aggregate purchase price of $350 million in cash, subject to certain adjustments. The sale follows the previously announced review of Masimo's consumer audio business and will sup.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $372 million, representing 10% on a reported basis; Non-GAAP revenue of $371 million, representing 10% on a constant currency basis(3); GAAP net income per diluted of $0.86; and Non-GAAP net income per diluted share(3) of $1.36, which grew 56% versus prior year period. First.

Samsung's Harman is set to pay around $350 million for the high-end audio-equipment maker.

MedTech companies' quarterly results are likely to reflect strength in customer demand. Let's see how FMS, MASI and CLOV are placed ahead of their earnings releases.

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Masimo (MASI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.